Skip to main content

Table 2 Demographic, pathologic and imaging features of HER + tumors according to hormone receptor status

From: Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Variable

Total cases (n = 61)

Mean ± SD

 

HER2+/HR− (n = 32)

Mean ± SD

 

HER2+/HR+ (n = 29)

Mean ± SD

 
 

No.

%

No.

%

No.

%

Age

      

  - < 50 years

26

42.6

8

25.0

18

62.1

  - ≥ 50 years

35

57.4

24

75.0

11

37.9

Pathological type

      

  - IDC

58

95.1

31

96.6

27

93.1

  - ILC

2

3.3

0

0

2

6.9

  - Clear cell carcinoma

1

1.6

1

3.1

0

0

Pathological grade

      

  - I & II

33

54.1

10

31.3

23

79.9

  - III

28

45.9

22

68.8

6

20.7

Mammography

      

Lesion

      

  - Mass

40

65.6

20

62.5

20

69.0

  - Architectural changes

10

16.4

3

9.4

7

24.1

  - Asymmetry

11

18.0

9

28.1

2

6.9

Calcifications

      

  - Yes

21

34.4

10

31.3

11

37.9

  - No

40

65.6

22

68.8

18

62.1

CESM

      

Size (cm)

5.0 ± 2.5

 

5.4 ± 2.3

 

5.9 ± 2.7

 

Focality

      

  - Unifocal

36

59.0

14

43.8

22

75.9

  - Multifocal

25

41.0

18

56.3

7

24.1

Shape

      

  - Round or oval

24

39.3

18

56.3

6

20.7

  - Irregular

37

60.7

14

43.8

23

79.3

Margin

      

  - Circumscribed

25

41.0

19

59.4

6

20.7

  - Irregular or spiculated

36

59.0

13

40.6

23

79.3

Enhancement pattern

      

  - Homogeneous

11

18.0

6

18.8

5

17.2

  - Heterogeneous

30

49.2

11

34.4

19

65.5

  - Ring

4

6.6

0

0

4

13.8

  - NME

16

26.2

15

46.9

1

3.4

  1. No, n number, y years, SD standard deviation, HER 2 human epidermal growth factor 2, IDC invasive ducal carcinoma, ILC invasive lobular carcinoma, CESM contrast-enhanced spectral mammography, NME non-mass enhancement